Drug Profile

CAL 101 - Calluna Pharma

Alternative Names: CAL-101 - Calluna Pharma

Latest Information Update: 23 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Calluna Pharma
Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
Mechanism of Action S100 calcium-binding protein A4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Fibrosis; Inflammation; Plaque psoriasis

Most Recent Events

18 Dec 2024 Calluna Pharma plans a phase II AURORA trial for Idiopathic pulmonary fibrosis (In adults, In the elderly) (IV), in May 2025 (NCT06736990)
24 Oct 2024 Pharmacokinetics and adverse events data from a Phase I trial in Plaque psoriasis released by Calluna Pharma
24 Oct 2024 Calluna Pharma completes a phase-I clinical trials in Plaque psoriasis in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com